CINECA IRIS Institutional Research Information System

GERMANI, MARCO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.006
AS - Asia 938
EU - Europa 530
SA - Sud America 161
AF - Africa 48
OC - Oceania 3
Totale 2.686
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 970
SG - Singapore 335
CN - Cina 268
IT - Italia 235
HK - Hong Kong 170
BR - Brasile 133
SE - Svezia 56
DE - Germania 49
GB - Regno Unito 47
KR - Corea 37
VN - Vietnam 29
FI - Finlandia 24
JP - Giappone 24
CI - Costa d'Avorio 21
IN - India 20
PL - Polonia 19
FR - Francia 17
BG - Bulgaria 15
NL - Olanda 15
CA - Canada 14
MX - Messico 13
RU - Federazione Russa 13
AR - Argentina 12
BD - Bangladesh 10
AT - Austria 9
SN - Senegal 7
IQ - Iraq 6
ZA - Sudafrica 6
EC - Ecuador 5
ES - Italia 5
LT - Lituania 5
TR - Turchia 5
UA - Ucraina 5
UZ - Uzbekistan 5
CZ - Repubblica Ceca 4
MA - Marocco 4
NG - Nigeria 4
EG - Egitto 3
HN - Honduras 3
ID - Indonesia 3
IE - Irlanda 3
PA - Panama 3
PH - Filippine 3
PK - Pakistan 3
PY - Paraguay 3
VE - Venezuela 3
AU - Australia 2
AZ - Azerbaigian 2
CH - Svizzera 2
MY - Malesia 2
OM - Oman 2
PE - Perù 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BY - Bielorussia 1
CL - Cile 1
CO - Colombia 1
DK - Danimarca 1
EE - Estonia 1
HR - Croazia 1
IR - Iran 1
JO - Giordania 1
KE - Kenya 1
KH - Cambogia 1
KW - Kuwait 1
KY - Cayman, isole 1
LA - Repubblica Popolare Democratica del Laos 1
LY - Libia 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
Totale 2.686
Salva come PNG Salva come JPEG
Città #
Singapore 198
Ashburn 168
Hong Kong 166
Dallas 148
Santa Clara 130
Shanghai 71
Hefei 53
Chandler 51
Los Angeles 42
Seoul 36
Beijing 33
Boardman 33
Milan 32
New York 31
Fairfield 29
Florence 29
London 23
Abidjan 21
São Paulo 19
Tokyo 18
Pisa 16
Cascina 15
Munich 15
Sofia 15
Warsaw 15
Bremen 12
Frankfurt am Main 12
Lawrence 12
Princeton 12
Ho Chi Minh City 11
Houston 11
Turku 11
Buffalo 10
Helsinki 10
Redondo Beach 10
Wilmington 10
Medford 9
Rome 9
Seattle 9
Chicago 8
Stockholm 8
Woodbridge 8
Dakar 7
Ogden 7
Rio de Janeiro 7
Toronto 7
Ann Arbor 6
Denver 6
Hanoi 6
Vienna 6
Cambridge 5
Chennai 5
Nuremberg 5
Quanzhou 5
Amsterdam 4
Atlanta 4
Boston 4
Brooklyn 4
Düsseldorf 4
Fuzhou 4
Kent 4
Lagos 4
Montreal 4
Mumbai 4
Orem 4
Polverigi 4
Porto Alegre 4
Turin 4
Verona 4
Bologna 3
Coreglia Antelminelli 3
Dublin 3
Fukuroi 3
Genoa 3
Guayaquil 3
Hyderabad 3
Istanbul 3
Johannesburg 3
Lucca 3
Manchester 3
Misinto 3
Panama City 3
Pistoia 3
Querétaro 3
San Diego 3
San Francisco 3
San Miniato Basso 3
Seacroft 3
Tashkent 3
Xiamen 3
Abingdon 2
Alghero 2
Anzio 2
Asunción 2
Baghdad 2
Baku 2
Belo Horizonte 2
Betim 2
Bexley 2
Buti 2
Totale 1.794
Salva come PNG Salva come JPEG
Nome #
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 133
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis 131
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features 126
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability 124
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm 112
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 111
Immune checkpoint inhibitors in pmmr metastatic colorectal cancer: A tough challenge 108
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 107
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors 106
A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma 102
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 102
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development 98
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 96
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer 93
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 89
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 87
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 86
The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients 80
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 77
Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy 68
EGFR Amplification in Metastatic Colorectal Cancer 68
null 65
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration 64
Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 60
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV 59
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 57
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience 55
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer 54
Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors 52
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 51
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies 50
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF V600E -mutated metastatic colorectal cancer treated with targeted therapy 49
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study 16
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials 8
Esperienze cliniche con encorafenib e cetuximab in pazienti con carcinoma metastatico del colon-retto con mutazione BRAFV600E dopo recidiva precoce alla chemioterapia adiuvante 6
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO 6
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials 6
Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments―analysis of 11 trials by AIO and GONO 4
Totale 2.766
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.369
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.369
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202158 0 0 0 0 0 38 0 0 4 1 0 15
2021/2022104 4 0 4 0 13 15 1 4 9 11 13 30
2022/2023240 22 36 17 14 17 26 6 13 52 0 31 6
2023/2024316 18 23 40 21 34 31 32 8 21 17 39 32
2024/20251.114 15 36 21 45 92 138 77 48 126 96 148 272
2025/2026922 137 211 151 172 204 47 0 0 0 0 0 0
Totale 2.766